Role of Colchicine in Prevention of Contrast Induced Nephropathy in Patient Undergoing Primary Percutaneous Coronary Intervention

Abstract

cute myocardial infarction is the most severe manifestation of coronary artery disease, which causes more than 2.4 million deaths in the USA, more than 4 million deaths in Europe and northern Asia, and more than a third of deaths in developed nations annually (Yeh et al., 2010 and Nichols et al., 2014). Primary PCI is the treatment of choice for acute coronary syndrome with STEMI (Saeed et al., 2012). CIN is an iatrogenic disease occurring after the intravascular injection of radiographic contrast media (Bartels et al., 1954). In 2004, CIN was indicated as the third leading cause of hospital-acquired acute renal failure (ARF) being responsible for 12% of all cases of ARF in hospital (Mussap & Merlini, 2014). In a cohort study, CIN incidence in STEMI patients undergoing primary PCI was 19.8% which was significantly higher than the known CIN incidence in patients undergoing elective PCI (1-3%) (Mehran & Nikolsky, 2006 and Koowattanatianchai et al., 2019).